The diagnosis of Waldenstr€ om Macroglobulinaemia (WM)/lymphoplasmacytic lymphoma (LPL) remains one of exclusion because other B-cell lymphoproliferative disorders (B-LPD), such as marginal zone lymphoma (MZL), can fulfil similar criteria, including MYD88 L265P mutation. It has been suggested that expression of the myeloid marker CD13 (also termed ANPEP) is more frequent in LPL than in other B-LPD and has also been described on normal and malignant plasma cells. Here, CD13 expression was tested in a cohort of 1037 B-LPD patients from 3 centres by flow cytometry. The percentage of CD13-expressing cells was found to be variable among B-LPD but significantly higher in WM/LPL (median 31% vs. 0% in non-WM/LPL, P < 0Á001). In multivariate linear regression, CD13 expression remained significantly associated with a diagnosis of WM/LPL (P < 0Á001). A cut-off value of 2% of CD19 + cells co-expressing CD13 yielded the best diagnostic performance for WM/LPL assertion. This was further improved by association with the presence or absence of IgM paraprotein. Finally, given that previously published transcriptomic data revealed no difference in CD13 (also termed ANPEP) mRNA between normal and pathological B-cells, the hypothesis of some post-transcriptional regulation must be favoured. These results suggest that testing for CD13 expression in routine flow cytometry panels could help to discriminate WM/LPL from other B-LPD.
exclusion, since other small B-cell lymphoproliferative disorders (B-LPD) fulfil similar criteria, especially marginal zone lymphomas (MZLs). Moreover, the WHO 2017 classification stated that "no specific chromosomal abnormalities are recognized" (Swerdlow et al, 2017 ). Yet, 6q deletion has been described in more than half of BM-based LPL, and trisomy 4 in approximately 20% of LPL, although these cytogenetic anomalies are indeed not specific of WM/LPL (Cook et al, 2005; Terre et al, 2006) . In addition to the MYD88 mutation, approximately 30% of the cases have truncated CXCR4 mutations (Swerdlow et al, 2017) . From an immunophenotypic point of view, WM/LPL cells are characterized by surface expression of B-cell associated antigens (CD19, CD20, CD22, CD79a) and membrane immunoglobulins light chain restriction. CD5, CD10, CD103 and CD23 are usually absent while CD25 and CD38 are frequently expressed (Lin et al, 2011) . However, a widely variable frequency of CD5, CD23 and CD10 positivity has been reported in WM/LPL (Hunter et al, 2005; Konoplev et al, 2005; Morice et al, 2009 ). Thus, WM/LPL do not display any truly specific immunophenotype and can also be misdiagnosed as another small B-LPD. Of course, morphological features, with the so-called "plasmacytic inflexion" may be of help but it requires the expertise of well-trained morphologists, which are not necessarily available in flow cytometry (FCM) core facilities.
As mentioned earlier, the MYD88 L265P mutation has been recognized to be present in about 90% of WM/LPLs (Treon et al, 2012) . However, this mutation is also present in a small proportion of IgM monoclonal gammopathies of unknown significance (MGUS), other small B-LPD (such as MZL) and, even more frequently, in diffuse large B-cell lymphomas (DLBCL) (Swerdlow et al, 2017) . Although the 2017 revision of the WHO classification acknowledges the diagnostic importance of the MYD88 L265P mutation in WM/ LPL (Swerdlow et al, 2017) , this does not exclude the need for other diagnostic markers of WM/LPL, because genetic testing is not readily available in all centres, and, when available, comes as a delayed result.
The CD13 differentiation antigen, originally identified as MCS-2, was recognized as a "panmyeloid" marker in the early 1980s (Gregg et al, 1984) and has been extensively used as a granulocytic and monocytic marker ever since. CD13, also known as Aminopeptidase N (ANPEP), is widely expressed on mammalian cells. This ectodipeptidyl-peptidase is involved in a variety of normal and malignant functions (Wickstrom et al, 2011) . Aberrant expression of CD13 has been described in acute lymphoblastic leukaemia (ALL) (Sobol et al, 1987; Lauria et al, 1994) and anaplastic large cell lymphomas (Bovio & Allan, 2008) , however reports of CD13 expression in mature lymphoid neoplasms are scarce. One study showed CD13 expression in several cases of small B-cell neoplasms [chronic lymphoid leukaemia (CLL), variant hairy cell leukaemia (HCL), other unspecified B-cell nonHodgkin lymphomas (NHL)] but not in mature T-cell neoplasms (Nakase et al, 1996) . Another work, focusing only on CLL, reported aberrant CD13 expression in 22% of cases (Pinto et al, 1991) . It has been suggested that aberrant expression of CD13 might be more frequent in LPL than in other small B-LPD (Craig & Foon, 2008) . Conversely, CD13 expression had long been reported on normal (Terstappen et al, 1990) and monoclonal (San Miguel et al, 1991; RuizArguelles & San Miguel, 1994) plasma cells.
In the present work, the value of testing for CD13 expression by FCM in the diagnosis of small B-LPD was investigated. CD13 expression was indeed found to be more frequent in WM/LPL and could thus be used as a relevant diagnostic marker.
Patients and methods

Patients
A cohort of 1037 patients issued from 3 centres [Linz (Austria), Paris and Bordeaux (France)] was included in this multicentre retrospective study. All patients were referred to the respective laboratories for immunophenotypic study and had a detectable monotypic B-cell population. Morphological, immunophenotypic, cytogenetic and molecular analyses, as well as clinical data, were collected in order to establish consensual integrated diagnoses according to the criteria of the WHO classification (Swerdlow et al, 2017) . The clinical and biological characteristics of the study population are reported in Table I .
All investigations were approved by local Ethics Committees and the procedures followed were in accordance with the Helsinki Declaration.
Flow cytometry (FCM)
All samples were immunophenotyped according to local procedures using 8-to 10-colour immunophenotyping panels on Navios (Beckman Coulter, Miami, FL, USA) or Canto II (BD Biosciences, San Jose, CA, USA) flow cytometers. B cells were gated according to CD19 expression, as illustrated in Fig 1. Details of the clones and fluorochromes used are given in Table I .
Transcriptomic studies
Previously published transcriptomic data available in the gene expression omnibus (GEO) repository (https://www.ncb i.nlm.nih.gov/geo/) for GSE6691 (Gutierrez et al, 2007) and GSE61597 (Paiva et al, 2015) were reanalysed using GEO2R (https://www.ncbi.nlm.nih.gov/geo/geo2r/).
Statistics
Categorical and continuous variables are reported as numbers and percentages, or median and percentiles, respectively. Group comparisons for dichotomic, categorical and Table I . Basic characteristics of the study population.
Median [IQR] 
Diagnosis
Chronic lymphocytic leukaemia 221 (61) 255 (46) 5 (4) 481 (46) <10
À4
Marginal zone lymphoma 42 (12) 89 (16) 24 (20) 155 (15) WM/LPL 35 (10) 65 (12) 11 (9) 111 (11) 0Á540 Follicular lymphoma 12 (3) 41 (7) 11 (9) 64 (6) Mantle cell lymphoma 20 (5) 17 (3) 23 (19) 60 (6) Hairy cell leukaemia 6 (2) 12 (2) 3 (2) 21 (2) Multiple myeloma 2 (1) 4 (1) 1 (1) 7 (1) Other B-NHL 22 (6) 71 (13) 45 (36) 138 ( Correlations between continuous variables were assessed by Spearman's correlation, using log-transformed values for white blood cell (WBC) and lymphocyte counts. The diagnostic performance of CD13 expression was assessed by nonparametric Receiver-Operator Characteristic (ROC) analysis. The optimal cut-off was defined by the maximum of Youden index, computed as (J = sensitivity + specificityÀ1). A multivariate diagnostic model for WM/LPL was then developed by logistic regression including all variables significantly associated with WM/LPL diagnosis in univariate analysis (P < 0Á05). Specification errors were checked by a link test and a Box-Tidwell model. Goodness of fit was inspected by the Hosmer and Lemeshow's test (Hosmer et al, 2013) . Collinearity was estimated with variance inflation factors (VIF), retaining the conventional VIF threshold of 4 as indicative of unacceptable collinearity (O'Brien, 2007 
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Results
Characteristics of the cohort
Demographic characteristics of the patients studied were globally similar across the 3 centres, with no significant differences in gender distribution nor age range (median age, 72 years; Table I ). A monoclonal paraprotein was present in 192 cases (26% of 725 patients with available data on immunofixation and/or immunoelectrophoresis), and was an IgM paraprotein in 150 of these cases (78%).
CD13 expression is highly variable among B-cell malignancies
The percentage of CD13-positive B cells expressed as median (5-95th percentiles) was 31% (0-100) in WM/LPL, and 0% in all other conditions, with variable ranges: 0-70 in MZL, 0-3 in CLL, 0-0 in follicular lymphoma (FL), 0-6 in mantle cell lymphoma (MCL), 0-1 in multiple myeloma (MM), 0-53 in HCL and 0-50 in other B-cell NHL (Table II and Fig 2) . Using the arbitrary positivity cut-off of 20%, commonly used in FCM, the number of patients with positive CD13 expression on B cells in each group was as follows: 71/ 111 (64%) in WM/LPL, 25/155 (16%) in MZL, 8/481 (1Á6%) in CLL, 1/64 (1Á5%) in FL, 2/60 (3%) in MCL, 0/7 (0%) in MM, 3/21 (14%) in HCL and 12/138 (8Á7%) in other B-cell NHL. These differences were statistically significantly different between groups (P < 0Á001, Table II and Fig 2) . The subgroup with the largest overlap to WM/LPL was that of MZL. Examination of the characteristics of these 25 CD13 + MZL patients disclosed that only 7 also had an IgM peak, but without low lymphocyte counts. Surprisingly, the percentage of CD13 + B cells was also found to be significantly different according to the sample source, regardless of the diagnosis, with a higher expression in BM samples: the percentage ranges were 0-58% in blood, 0-61% in BM, 0-0% in lymph nodes and 0-30% in other sources (P < 0Á001, Table II and Fig 3) .
CD13 expression is highly associated with a WM/LPL diagnosis
Screening baseline characteristics of the 1037 patients of the cohort revealed five variables associated with CD13 expression (Table II) . When analysed as continuous parameter, CD13 expression was higher in patients with WM/LPL diagnosis (P < 0Á001), BM vs. other sample source (P < 0Á001), presence of a monoclonal paraprotein (n = 725, P < 0Á001), IgM paraprotein (n = 723, P < 0Á001) and lower lymphocyte count (n = 671 for patients who had CD13 expression measured in a blood sample, P = 0Á03). There was no significant (Table II) . Using ROC curves (Fig 4) and Youden index, the discriminating CD13-positivity threshold was defined as 2% CD13 + B cells [AUC = 0Á9012 (95% CI = 0Á87-0Á93)]. With this cut-off, the sensitivity for the diagnosis of WM/LPL was 88Á3% (95% CI = 80Á8-93Á6) and specificity was 87Á9% (95% CI = 85Á6-90Á0). The PPVwas 46Á7% (95% CI = 39Á8-53Á7) and NPV was 98Á4% (95% CI = 97Á3-99Á2). In the following analyses, CD13 positivity refers to samples with ≥2% CD13 + B cells.
Parameters associated with a WM/LPL diagnosis were tested using univariate analysis (Table III) . A WM/LPL diagnosis was found to be significantly associated with CD13 expression ≥2% (P < 10 À4 ), presence of a monoclonal paraprotein (P < 10 À4 ), IgM paraprotein (P < 10 À4 ),
higher WBC (P = 0Á0002) and lymphocyte counts (P < 10 À4 ) and higher total M paraprotein level (P = 0Á0032). We next performed a multivariate logistic regression model considering all variables significantly associated with WM/LPL diagnosis (P < 0Á05), i.e. CD13 positivity, presence of an IgM paraprotein, lymphocyte count (but not WBC count for obvious collinearity issues) in the 667 patients with available information on paraproteins, adjusting for sample source (BM versus others) and centre. CD13 ≥ 2% remained a predictor of WM/LPL diagnosis [odds ratio (OR) = 57Á55; P < 10 À4 ], independently of the presence of an IgM paraprotein (OR = 18Á33; P < 10 À4 )
while lymphocyte counts no longer predicted WM/LPL (P = 0Á429, Table IV ). Importantly, the predictive role of CD13 positivity was also independent of sampling in the BM versus other tissues, and there was no significant collinearity between the presence of an IgM paraprotein, BM sampling nor CD13 positivity. Receiver-operator-characteristic (ROC) curve for CD13. Area under the curve = 0Á9012, 95% confidence interval (CI) = (0Á87-0Á93). With a threshold of 2%, sensitivity and specificity are 88Á3% (95% CI: 80Á8-93Á6%) and 87Á9% (95% CI: 85Á6-89Á9%), respectively. Table III . Association of study parameters with WM/LPL diagnosis using univariate analysis.
Quantitative parameter
Mean AE SD of parameter P value WM/LPL diagnosis Other B-cell malignancies
Qualitative parameter The performance of the association of CD13 ≥ 2% and IgM paraprotein as diagnostic markers was then tested. Expression of CD13 above 2% was significantly associated with a diagnosis of WM/LPL whether or not the patients presented with an IgM paraprotein. In patients with an IgM paraprotein (n = 150), CD13 ≥ 2% had a PPV of 79Á2% (95% CI: 70Á0-86Á8%) and an NPV of 77Á8% (64Á4-88Á0%), while in patients without an IgM paraprotein (n = 573), the PPV was only 21Á2% (12Á9-31Á8%) yet the NPV was 100% (99Á2-100%).
CD13 expression could be regulated at a posttranscriptional level
Retrospective analysis of previously published transcriptomic data (Gutierrez et al, 2007; Paiva et al, 2015) revealed no significant difference between CD13 expression in normal or pathological B cells at the mRNA level (Fig 5) . CD13 (ANPEP) mRNA expression was not significantly different in plasma cells compared to lymphocytes in healthy donors (Fig 5A) , although CD13 expression can be observed on normal plasma cells by FCM at various levels (0-70% in our experience, unpublished personal data) but not on normal or reactive B cells (unpublished personal data). CD13 mRNA expression was strictly comparable between normal BM cells from healthy donors and B cells from WM patients (Fig 5B) . These observations indicate that CD13 transcripts can be produced at various stages of B-cell differentiation but only result in protein expression in a selected cluster of B-lineage malignancies. Indeed, with the methodology used for mRNA analysis, similar levels would yield a "neutral" signal. This is therefore highly suggestive of an unexpected significant level of transcription of the CD13 gene, regulated at later stages in most B cells so as not to translate in surface expression of the protein.
Discussion
This study reports that CD13 surface expression is significantly higher in WM/LPL compared to other small B-LPDs. CD13 expression is also higher in BM compared to other sample sources. CD13 expression was found to be significantly associated with the diagnosis of WM/LPL, the presence of a monoclonal paraprotein of IgM isotype and a lower total lymphocyte count. These criteria can be used to consolidate a diagnosis of WM/LPL and, perhaps more importantly, to rule out the diagnosis of WM /LPL when both CD13 expression and IgM paraprotein are absent (NPV 100%). Of note, although 7 MZL patients with CD13 expression also had an IgM paraprotein, none of them had lowered lymphocyte counts and morphological characteristics would have also helped to rule out a diagnosis of WM/LPL in these 4Á5% of MZL cases. In the past few years, the MYD88 L265P mutation has emerged as a strong characteristic feature of WM/LPL (Swerdlow et al, 2017) that could be used for diagnosis. In the literature, MYD88 mutation detection has been reported to have a sensitivity of 96-100%, a specificity of 92-97%, a PPV of 86-96% and a NPV of 99-100% for WM diagnosis, depending on the series and the detection techniques used (Xu et al, 2013; Hunter et al, 2014; Insuasti-Beltran et al, 2015) . By comparison, the threshold of 2% of CD19 + cells for CD13 positivity in the more rapid method of FCM that we propose, although showing a slightly lower discrimination, retains strong performance. Moreover, this study included all types of B cell neoplasms whereas the diagnostic power of MYD88 L265P mutation has mainly been studied in IgM gammopathies with a large majority of WM. It must be considered that CD13 testing is readily available in all FCM core facilities, where lymphoproliferative disorders and acute leukaemia are routinely diagnosed, and can be easily added to FCM panels for mature lymphoid neoplasms. By contrast, as mentioned above, MYD88 mutational status assessment is not available everywhere and the results of this molecular test are delayed compared to the rapid assessment of FCM evaluation on fresh cells (within half a day). The aminopeptidase-N CD13 molecule is an ubiquitous protein involved in a variety of functions in physiological or malignant contexts, such as peptide cleavage, solid tumour cell invasion, differentiation, proliferation and apoptosis, cell motility, chemotaxis, antigen presentation, phagocytosis, angiogenesis and cell adhesion (Mina-Osorio, 2008; Wickstrom et al, 2011) . However, its role in lymphoid cells remains elusive. CD13 expression is observed on haematopoietic stem cells and at the earliest stages of both B-and T-lymphoid maturation, but is then lost as lymphoid maturation progresses (Syrjala et al, 1994; Spits et al, 1995) . Interestingly, data observed in CLL patients showed a correlation between CD13 expression on neoplastic lymphocytes and the pattern of BM infiltration and prognosis (Pinto et al, 1991) . Moreover, CD13 has been implicated in the adhesion of B-and T-lymphocytes to fibroblasts and other cell types (Riemann et al, 1997) . Given the importance of the BM microenvironment in the pathogenesis of WM (Agarwal & Ghobrial, 2013) , CD13 could play a major role in the interaction of lymphoplasmacytic cells with the stroma. Our results also show a link between CD13 expression and the presence of a paraprotein (IgM or other isotypes). It can therefore be hypothesized that CD13 might play a role in paraprotein secretion, although no data in the literature suggest such an implication of CD13 in secretory functions. Finally, given that similar mRNA levels of CD13 transcripts are observed in a variety of normal or pathological B cells, it can be suggested that the mechanisms impairing translation of these transcripts are altered in WM/LPL. The fact that MYD88 is a protein involved in mRNA stabilization (Sun & Ding, 2006) might not be alien to this observation.
